CYTK Mizuho raised the firm's price target on Cytokinetics to $118 from $100 and keeps an Outperform rating on the shares. The firm updated
CYTK Mizuho raised the firm's price target on Cytokinetics to $118 from $100 and keeps an Outperform rating on the shares. The firm updated the company's model following the Q1 report.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.